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Abstract:  Marine  carotenoids  are  important  bioactive  compounds  with  physiological 
activities related to prevention of degenerative diseases.found principally in plants, with 
potential  antioxidant  biological  properties  deriving  from  their  chemical  structure  and 
interaction  with  biological  membranes.  They  are  substances  with  very  special  and 
remarkable properties that no other groups of substances possess and that form the basis of 
their many, varied functions and actions in all kinds of living organisms. The potential 
beneficial effects of marine carotenoids have been studied particularly in astaxanthin and 
fucoxanthin as they are the major marine carotenoids. Both these two carotenoids show 
strong  antioxidant  activity  attributed  to  quenching  singlet  oxygen  and  scavenging  free 
radicals. The potential role of these carotenoids as dietary anti-oxidants has been suggested 
to  be  one  of  the  main  mechanisms  for  their  preventive  effects  against  cancer  and 
inflammatory diseases. The aim of this short review is to examine the published studies 
concerning  the  use  of the two  marine carotenoids,  astaxanthin  and  fucoxanthin, in the 
prevention of cardiovascular diseases. 
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1. Introduction 
Cardiovascular disease (CVD), especially coronary heart disease (CHD) and stroke, is the leading 
killer in Western Society and its prevalence is increasing dramatically in developing nations [1]. 
Atherothrombotic  disease  is  the  consequence  of  conventional  risk  factors  such  as  smoking, 
hypertension, hyperlipidemia, insulin resistance and diabetes, and obesity. Novel risk factors include 
highly  sensitive  C-reactive  protein  (hs-CRP)  and  other  markers  of  inflammation,  homocysteine,  
and lipoprotein (a) [2].  
Along with
 genetic factors and age, lifestyle and diet are also considered
 important risk factors. 
Reduction in dietary consumption of animal fat, cholesterol, and sodium should be the mainstay of 
population-wide CHD prevention [3]. Dietary interventions should be the initial step in the treatment 
of CVD. In particular, a group of phytochemical substances in carotenoids which is responsible for the 
color of food play an important role in the prevention of human diseases and the maintenance of 
good health [4]. 
2. Oxidative Stress and Antioxidants  
Oxidative modification of low density lipoprotein cholesterol (LDL-C) play an important role in the 
initiation and progression of the atherosclerotic process, a continuum pathophysiological process that 
includes oxidative stress, endothelial dysfunction, inflammatory process, and vascular remodelling [5].  
Specifically, CVD are associated with increased production of reactive oxygen species (ROS) and a 
compromised  endogenous  anti-oxidant  defense  system.  Oxidative  stress  is  tightly  regulated  by  a 
balance between production and removal of ROS [6], which are natural by-products of metabolism 
with important roles in cell signaling. However, excessive levels of ROS can be toxic to cells, i.e., 
whenever the  expression of anti-oxidant  enzymes, including superoxide  dismutases  (SODs),  heme 
oxygenase-1 (HO-1), NAD(P)H quinine oxidoreductase-1 (NQO-1), catalase and thioredoxin are not 
sufficient  to  control  ROS  and  minimize  ROS-induced  damage  [7].  A  compromised  anti-oxidant 
defense system can lead to excessive oxidative stress and ultimately result in cell damage [8]. 
Numerous studies indicate that increased oxidative stress may be involved in the pathogenesis of 
CVD. Several animal models suggest that when endogenous anti-oxidant systems are overwhelmed, 
exogenous antioxidant supplementation can be used for preventive and/or therapeutic intervention of 
oxidative  cardiovascular  disorders  [9].  In  particular,  SODs,
  catalase  and  glutathione  peroxidase 
(GSHPx) are endogenous natural antioxidants present within
 human cells. In addition, antioxidants such 
as vitamin E, vitamin
 C, polyphenols and carotenoids are available from foods [10].  
Current  dietary  guidelines  to  combat  chronic  diseases,  including  cancer
  and  CHD,  recommend 
increased  intake  of  plant
  foods,  including  fruits  and  vegetables,  which  are  rich  sources
  of  
antioxidants  [11].  The  role  of  such  dietary  antioxidants  in  disease
  prevention  has  received  much 
attention  recently  and  appears  to  have  a  wide  range  of  antiatherogenic  properties  [12,13].  These 
observations
 may explain the epidemiological data indicating that diets rich
 in fruits and vegetables are 
associated with a reduced risk
 of numerous chronic diseases [14].
  
Carotenoids are ubiquitous in nature and present in plants, algae and microorganisms. However, 
humans and other animals are unable to manufacture carotenoids and hence require these in their diet. Mar. Drugs 2011, 9  
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There  are  two  class  types  of  carotenoids  based  on  their  chemical  composition:  carotenes  and 
xanthopylls [15]. Astaxanthin and fucoxanthin are major marine carotenoids. Both these carotenoids 
show  strong  antioxidant  activity  which  is  attributed  to  quenching  singlet  oxygen  and  scavenging  
free radicals (FRs) [16]. 
3. Astaxanthin  
3.1. Chemical Structure and Mechanism of Action 
Astaxanthin is a xanthophyll carotenoid which contains two additional oxygenated groups on each 
ring structure compared with other carotenoids, resulting in enhanced antioxidant properties, approved 
in  the  1999  as  a  dietary  supplement  by  Food  and  Drug  Amninistration.  This  compound  occurs 
naturally  in  a  wide  variety  of  living  organisms  including  microalgae  (Haematococcus  pluvialis, 
Chlorella zofingiensis, and Chlorococcum sp.), fungi (red yeast Phaffia rhodozyma), complex plants, 
seafood, and some birds such as flamingos and quail; it is reddish-coloured, and gives salmon, shrimp 
and lobster their distinctive colouration [17]. The microalga H. pluvialis has the highest capacity to 
accumulate  astaxanthin  up  to  4–5%  of  cell  dry  weight.  Astaxanthin  has  been  attributed  with 
extraordinary  potential  for  protecting  the  organism  against  a  wide  range  of  diseases,  and  has 
considerable potential and promising applications in the prevention and treatment of various diseases, 
such as cancers, chronic inflammatory diseases, metabolic syndrome, diabetes, diabetic nephropathy, 
CVD, gastrointestinal and liver diseases, and neurodegenerative diseases [18]. 
Astaxanthin cannot be manufactured in animals or converted to vitamin A and therefore must be 
consumed in the diet. Xanthophyll carotenoids such as astaxanthin and canthaxanthin have antioxidant 
activity, are free radical scavengers, potent quenchers of ROS and nitrogen oxygen species (NOS), and 
chain-breaking  antioxidants.  They  are  superior  antioxidants  and  scavengers  of  free  radicals  (FRs) 
compared to the carotenoids such as -carotene [19].  
Available  forms  of  astaxanthin  are  represented  by  natural  forms  on  an  industrial  scale  of  
production [20,21]. The disodium disuccinate astaxanthin (DDA), a synthetic form of astaxanthin, 
overcame  the  limitations  of  caroteniods  related  to  their  poor  aqueous  solubility  and  enabled 
investigation of this agent in the animal models of myocardial ischaemia and reperfusion using both 
intravenous and oral routes of administration [22]. DDA has been shown to be very effective in animal 
cardiovascular studies administered both intravenously and orally [23–25].  
3.2. Astaxanthin and Cardiovascular Disease: Experimental Studies 
Astaxanthin has undergone investigation in a large number of experimental studies related to the 
cardiovascular and cerebrovascular systems. Only few studies have investigated the potential benefits 
of astaxanthin in human health and disease and most of these have been performed in healthy volunteers 
to assess dosing [26], bioavailability [27,28], safety [29], oxidative stress, and inflammation [26,30].  
Studies  conducted  in  healthy  human  volunteers  have  found  significant  reductions  in  oxidative 
stress, hyperlipidemia and inflammatory markers after astaxanthin oral supplementation. In particular, 
Cicero et al. [31] have demonstrated that food supplements for four weeks containing a combination of 
natural products such as berberine, policosanol, red yeast extracts, folic acid and astaxanthin could be a Mar. Drugs 2011, 9  
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useful support to diet and life style changes to correct dyslipidemias and to reduce cardiovascular (CV) 
risk  in  40  subjects  with  moderate  mixed  dyslipidemias.  In  this  study  total  cholesterol  (TC),  
LDL-C,  high  density  lipoprotein  cholesterol  (HDL-C),  non  HDL-C,  Apo-B,  Apo-A,  Lp(a)  and 
triglycerides (TG) were measured before and at the end of treatments. Berberine and combinations of 
natural products (policosanol, red yeast extracts, folic acid and astaxanthin) significantly reduced TC 
(respectively by 16%  and  20%), LDL-C (by 20%  and  25%), Apo-B (by  15%  and  29%) and  TG  
(by 22% and 26%), and increased HDL-C (by 6.6% and 5.1%). Even Yoshida et al. [32] demonstrated 
in  a  randomized,  placebo-controlled  human  study  (61  non-obese  subjects  aged  20–65  years)  that 
astaxanthin consumption (0, 6, 12, 18 mg/day for 12 weeks) ameliorates TG and HDL-C in correlation 
with increased adiponectin in humans. In this study, before and after tests, body mass index (BMI) and 
LDL-C were unaffected at all doses, however, TG decreased, while HDL-C increased significantly. 
Multiple comparison tests showed that 12 and 18 mg/day doses significantly reduced TG, and 6 and  
12 mg doses significantly increased HDL-C. Serum adiponectin was increased by astaxanthin (12 and  
18 mg/day), and changes of adiponectin correlated positively with HDL-C changes independent of  
age  and  BMI.  Iwamoto  et  al.  [26]  demonstrated  a  significant  inhibition  of  LDL-C  oxidation  in 
24 healthy volunteers who took doses of astaxanthin (1.8, 3.6, 14.4 and 21.6 mg/day for 2 weeks).  
Even  Karppi  et  al.  [30]  in  a  12-week  randomized  double-blind  study  involving  40  healthy  
non-smoking Finnish males assessed a significant plasma reduction levels of 12- and 15-hydroxy fatty 
acids in those taking astaxanthin (8 mg/day) suggesting an important reduced fatty acid oxidation due 
to astaxanthin.  
4. Fucoxanthin 
4.1. Chemical Structure and Mechanism of Action 
Fucoxanthin is a naturally occurring brown pigment that belongs to the class of non-provitamin A 
carotenoids, a class of 40-carbon organic molecules that consist of two groups: xanthophylls if their 
structure contains oxygen, and carotenes if there is no oxygen in their chemical formula. Fucoxanthin 
is  a  xanthophyll  whose  distinct  structure  includes  an  unusual  allenic  bond,  epoxide  group  and 
conjugated carbonyl group in polyene chain [33] with antioxidant properties [34]. The difference, 
however is that fucoxanthin acts as an antioxidant under anoxic conditions whereas other carotenoids 
have practically no quenching abilities. Most tissues under physiological conditions have low oxygen 
presence. Furthermore, the typical antioxidants are usually proton donors (ascorbic acid, α-tocopherol, 
glutathione). Fucoxanthin, on the other hand, donates electron as a part of its free-radical quenching 
function. A combination of these distinct properties is very rarely found among naturally occurring 
food-derived compounds [35,36]. During normal metabolism the body produces heat. Fucoxanthin 
increases the amount of energy released as heat in fat tissue, a process also called thermogenesis.  
A  published  study  reports  that  fucoxanthin  affects  multiple  enzymes  involved  in  fat  metabolism 
causing an increase in the production of energy from fat [37]. Mar. Drugs 2011, 9  
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4.2. Fucoxantin and Cardiovascular Disease: Experimental Studies (Human and Animal) 
Experiments  on  stroke-prone  spontaneously  hypertensive  rats  (SHRSP)  show  the  possible 
protective role of fucoxanthin in CVD. Thirty-three male SHRSP rats, 5 weeks of age, were purchased 
from the Disease Model Cooperative Research Association (Kyoto, Japan). Animals were divided into 
three  groups:  (1)  kaolin  group,  which  was  given  a  normal  diet  [5%  (w/w)  kaolin,  a  non-nutrient 
material];  (2)  Wakame  (Undaria  Pinnatifida)  group  [normal  diet  containing  5%  (w/w)  Wakame 
powder]; and (3) cellulose group [normal diet containing 5% (w/w) cellulose]. In this study, Wakame 
delayed the incidence of stroke signs and increased the life span of SHRSP. Wakame did not attenuate 
the development of hypertension in SHRSP [38].  
Thrombosis  is  a  major  complication  of  coronary  atherosclerosis  that  can  lead  to  myocardial 
infarction.  Docosahexaenoic  acid  (DHA)  inhibits  the  synthesis  of  thromboxane  A2  (TxA2)  from 
arachidonic acid (AA) in platelets [39]. In addition, DHA enhances the production of prostacyclin, a 
prostaglandin that produces vasodilation and less sticky platelets [40]. Also epidemiologic and clinical 
trials demonstrated that fish oil such as eicosapentaenoic acid (EPA) and DHA, decreased LDL-C, TG 
and increased HDL-C concentrations. DHA content in fish oil fed to experimental animals inhibits the 
development of atherosclerosis, so the fucoxanthin may have an potential role in the modulation and 
prevention of human diseases, particularly to reducing the incidence of CVD [41,42].  
4.3. Fucoxantin and Metabolic Syndrome: Experimental Studies (Human and Animal) 
Among marine carotenoids, attention has been paid towards fucoxanthin in recent years, that is 
actually used for the treatment of methabolic syndrome and obesity [43], two important risk factors of 
CVD.  Fucoxanthin  has  a  unique  structure  including  an  allenic  bond  and  5,6-monoepoxide  in  
the  molecole,  is  a  major  carotenoid  found  in  edible  sceaweeds  such  as  Undaria  pinnatifida, 
Hijikia fusiformis and Sargassum fulvelum [44]. This molecule is under study for possible application 
in the fight against overweight and obesity since it promotes the reduction of abdominal fat. In this 
regard it is interesting to note an increased concentration of fat in the abdomen statistically correlated 
with an increased risk of CVD. A study conducted by Maeda et al. [43] in male Wister rats and female 
KK-Ay  mice  under  different  experimental  diets  (soybean  oil,  Undaria  lipids,  Undaria  glycolipid 
fraction, crude fucoxanthin and purified fucoxanthin fed to different concentration according to their 
groups) for 4 weeks shows that Undaria lipids (containing 9.6% fucoxanthin) reduced significantly the 
weights of abdominal white adipose tissue (WAT) of both rats and mice. Body weights of mice fed 
Undaria  lipid  was  significantly  lower  than  that  of  controls  [45].  Animal  studies  by  one  group  of 
researchers suggest that fucoxanthin might prevent the growth of fat tissue and reduce abdominal fat, 
has a beneficial effects in stroke prevention, reduction of inflammation, and slowing the growth of 
various cancer cell type [38,45]. Woo et al. [37] in a recent study shows as, the fucoxanthin facilitates 
youthful energy metabolism by activating a special cellular mitochondrial protein called UCP-1, which 
induces the thermogenesis. This is important because obesity markedly increases the risk of CVD. 
Fucoxanthin has been found to reduce blood glucose in animals with diabetes and in normal mice that 
are fed high fat diets [46]. It appears that fucoxanthin is capable of upregulating glucose transporter, 
mRNA  expression  of  L6  myotubes  which  are  responsible  for  glucose  transport  in  adult  muscle  Mar. Drugs 2011, 9  
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tissue [47]. An interesting, extra, metabolic benefit of fucoxanthin administration in rodents is the 
promotion of the synthesis of DHA in the liver [43]. 
Because  the  metabolic  syndrome  is  a  collection  of  risk  factors  that  substantially  increase  the 
chances of damage in the CVS, which can lead to a heart attack or stroke, the importance of the 
fucoxanthin  in  the  regular  metabolic  syndrome  would  be  very  important  to  prevent  CV  damage. 
Clinical research also indicated that the metabolic boost from taking fucoxanthin did not stimulate the 
central nervous system, meaning it did not cause the jitters or lost sleep like caffeine, nicotine, or 
thyroid hormones. Only one study has currently been conducted in humans which has evaluated the 
effectiveness of fucoxanthin supplementation for weight loss. This study reports that the supplement, 
Xanthigen, which contains 300 mg pomegranate seed oil and 300 mg brown marine algae fucoxanthin 
significantly increased weight loss and reduced body and liver fats content in obese women treated for 
16 weeks [48]. 
Fucoxanthin proved safe with no side effects, and even provided other health benefits, including 
improved cardiovascular health, reduction of inflammation (a major cause of heart disease), healthy 
cholesterol and TG levels, improvements in blood pressure levels, and healthy liver function [49–51]. 
5. Conclusion 
Oxidative stress and inflammation play an important role in the pathophysiology of many chronic 
diseases  including  CVD  [52].  The  xanthophyll  carotenoid  dietary  supplement,  astaxanthin,  has 
demonstrated to be a potential antioxidant and anti-inflammatory therapeutic agent in models of CVD. 
There  have  been  human  clinical  studies  using  astaxanthin  to  assess  its  safety,  bioavailability  and 
clinical aspects relevant to oxidative stress and inflammation in CVS. There were no adverse effects 
reported. These demonstrated reduced markers of oxidative stress and inflammation and improved 
blood rheology. Astaxanthin has great potential as a potent antioxidant to be tested in human clinical 
trials  based  on  theoretical  grounds  related  to  its  physicochemical  properties  and  on  the  basis  of 
exciting preliminary experimental studies in CV models. Although its use in human clinical studies has 
been  limited,  so  far  no  safety  concerns  have  arisen  [53].  We  predict  that  because  of  its  greater 
antioxidant potency and membrane preservation, astaxanthin will reduce measures of oxidative stress 
and inflammation and provide vascular benefits [54].  
The  versatile  effects  of  fucoxanthin  on  intermediate  metabolism  make  this  carotenoid  of  great 
potential value in the prevention or management of the metabolic syndrome and obesity. The animal 
experiments  with  fucoxanthin  stimulated  researchers  to  recommend  human  clinical  trials  with 
fucoxanthin.  As  a  carotenoid,  fucoxanthin  is  a  powerful  antioxidant  that  protects  cells  from  FRs 
damage. Future clinical studies and trials will help determine the efficacy of these marine carotenoids 
(asthaxantin and fucoxanthin) on vascular structure, function, oxidative stress and inflammation in a 
variety of patients at risk of, or with established CVD. These may lead to large interventional trials 
assessing CV morbidity and mortality. 
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